What Дузофарм Treats: Main Uses and Benefits

The medication is commonly used in situations involving certain distressing symptoms across a range of peripheral vascular disorders, providing supportive relief for symptoms related to physical discomfort.

---

Key Therapeutic Focus and Benefits

Дузофарм is primarily used to address symptom clusters that may become intense or disruptive in conditions like intermittent claudication, Raynaud's syndrome, trophic ulcers, and cerebrovascular insufficiency.

For patients experiencing mobility-limiting leg pain, the therapeutic benefit supports the management of symptoms that interfere with daily functioning. This may assist with maintaining functional stability and helps patients cope more steadily with the difficult episodes imposed by the condition. The medication is also relevant for easing symptoms of severe localized discomfort, such as chronic rest pain and night cramps. It contributes to easing the overall symptom load in conditions where symptoms relate to organ-specific functional stress. This provides support that helps ease the overall symptom burden.

---

Quick Fact: Relief for Vascular Symptoms

Symptom Category	Supportive Benefit
Mobility Pain (Claudication)	Assists with managing symptoms of physical discomfort that interfere with daily functioning.
Tissue Stress (Ulcers, Rest Pain)	Plays a role in managing symptoms linked to severe localized discomfort.
Functional Stability (Cerebral)	Assists with managing symptoms that create noticeable physiological strain and affect functional stability.

Who Can and Cannot Use Дузофарм?

The eligibility for using Дузофарм (Naftidrofuryl oxalate) is strictly determined by regulatory guidelines concerning age, specific comorbidities, and physiological status.

Eligible Population

The medication is indicated for use exclusively in adults for the management of symptoms associated with various peripheral vascular disorders, as its safety profile is established only within this age group.

Absolute Contraindications

Дузофарм must not be used in patients with a known hypersensitivity to the active substance or excipients. It is also strictly prohibited for individuals with a history of hyperoxaluria or recurrent calcium-containing kidney stones, due to the drug's oxalate salt content.

️ Use Restrictions and Limitations

Population Group	Regulatory Status and Restriction
Children (Paediatric)	Safety and efficacy have not been established; the drug is not indicated for use.
Pregnant Patients	Use is not advisable due to lack of sufficient clinical safety data.
Breast-Feeding Patients	Should not be used due to a lack of data on excretion into breast milk.
Comorbidities	Avoidance is required in patients with severe cardiac conduction abnormalities or a recent cerebrovascular event.

Interactions with other medicines and products

The interaction profile for Naftidrofuryl oxalate is formally defined by its documented effects on certain metabolic pathways and its potential for combined physiological effects with co-administered substances. The primary pharmacokinetic interaction involves the Cytochrome P450 2D6 (CYP2D6) enzyme system.

Pharmacokinetic (PK) Interactions

Regulatory documentation states that Naftidrofuryl is metabolized by this enzyme. Consequently, co-administration with other medicinal products known as strong CYP2D6 inhibitors, such as quinidine or fluoxetine, may cause an increase in the plasma concentration of Naftidrofuryl oxalate, thereby increasing systemic exposure. Conversely, Naftidrofuryl itself is also noted as a weak to moderate inhibitor of CYP2D6, suggesting the potential to increase the exposure of other medicines that are substrates for this enzyme.

Pharmacodynamic (PD) and Substance Interactions

A critical area of interaction is pharmacodynamic, concerning blood pressure regulation. Official government sources advise caution when co-administered with other medicinal products that possess a hypotensive effect. This specifically applies to medicines like beta-blockers and Monoamine Oxidase Inhibitors (MAOIs), where an additive reduction in blood pressure is documented as a risk. Furthermore, regulatory labels include a specific caution regarding the consumption of alcohol, which is also documented to contribute to the vasodilatory and hypotensive effect. No mandatory timing-based separation rules or formally contraindicated combinations are listed in the regulatory interaction summaries.

The mechanism of Düzofarm involves a complementary dual action on both the peripheral vascular system and cellular energy metabolism, which constitutes a physiological response that addresses both vascular tone and cellular energy stability.

Modulating Vascular Tone via 5-HT2A Receptor Antagonism

This domain focuses on the drug's action as a selective antagonist at the 5-HT2A receptors found primarily on peripheral blood vessels. By occupying these receptors, the molecule suppresses serotonin-mediated signals that cause contraction of arterial smooth muscle. This mechanism results in peripheral vasodilation, physically increasing the diameter of the blood vessels and thus leading to an increase in the gross delivery of blood and oxygen into the capillary beds.

Enhancing Cellular Energy Metabolism

This domain involves the drug's distinct action as a non-competitive inhibitor of Succinate Dehydrogenase (SDH), a key enzyme in the cell's mitochondrial energy production (Complex II). By modulating the efficiency of the aerobic metabolic pathway, Düzofarm induces a metabolic shift in cellular processes. This metabolic modulation helps to preserve the cell's energy (ATP) stores and enhances the effective utilization of residual oxygen, which contributes to the maintenance of cellular function even during periods of oxygen deprivation.

Administration Guidelines for Дузофарм

The use of Дузофарм (Duzopharm) is governed by specific instructions provided for the medication. The daily dose must be administered in two equally divided doses, approximately twelve hours apart.

Dosing and Administration

Administration Scope	Standard Instruction
Route of Administration	Oral use (tablets or solution) or Intravenous (IV) use (concentrate for infusion).
Standard Dosing Schedule	Therapy typically initiates at 500 mg twice daily (b.i.d.). The total daily dose is progressively increased, based on the prescribed regimen, up to a maximum recommended daily dose of 3000 mg.
Timing in Relation to Meals	The medicine can be taken with or without food.

Tablets should be swallowed whole with a sufficient quantity of liquid. If the oral solution is used, the exact prescribed volume must be measured using a calibrated measuring device. For the IV form, the concentrate must be diluted in a compatible solution (e.g., 100 mL of 0.9% Sodium Chloride) and administered as an infusion over 15 minutes.

Population-Specific Instructions

Dose adjustments are required for patients with impaired renal function, determined by their estimated creatinine clearance (CLcr). Pediatric dosing is weight-based, with the oral solution being the mandatory formulation for infants and preferred for children who cannot swallow tablets. If a dose is missed, the standard protocol is to skip the missed dose if it is almost time for the next scheduled dose; taking two doses simultaneously is forbidden. Treatment must be discontinued gradually by reducing the dose over a period of two to four weeks.

Research Evidence Overview for Дузофарм

This section summarizes the official research—primarily clinical trials and meta-analyses—that regulators rely on to support the approved indications for Naftidrofuryl oxalate, focusing only on the structure of the evidence, not clinical advice. Studies help show what has been observed so far, providing context but not individual predictions.

---

Evidence for Managing Mobility Symptoms in Intermittent Claudication

Research for intermittent claudication (mobility-limiting leg pain) primarily involves well-structured, intermediate-term Randomized, Controlled Trials (RCTs). This research was evaluated in patients with stable symptoms characterized by functional limitations. Studies explored outcomes related to physical discomfort by measuring Pain-Free Walking Distance (PFWD) and Maximal Walking Distance.

Studies report on the analysis of objective walking distances measured over observation periods usually lasting three to six months, including comparisons to populations receiving a placebo. The evidence describes short-term symptom patterns in the observed populations.

What remains uncertain is the long-term data regarding the continuation of observed outcomes. Long-term effects are not fully established, as follow-up durations were limited in key reviews. There is limited information for long-term outcomes related to major clinical events, such as the progression of the underlying vascular disease.

---

Evidence for Supporting Other Peripheral Circulation Symptoms

Research explored the assessment of outcomes in conditions involving periods of heightened symptoms related to localized tissue stress, such as night cramps, rest pain, and skin ulceration. Research examined outcomes related to physical discomfort. Evidence for these distinct symptom clusters relies on individual clinical trials rather than being the main focus of recent systematic reviews. Findings describe patterns observed in these individual studies. However, evidence quality varies across studies, and data for certain groups remain insufficient.

---

What is Still Uncertain About Дузофарм Research

Follow-up durations were limited in the most robust trials, meaning long-term effects are not fully established. Evidence quality varies across studies, particularly when looking beyond the primary indication. Comparative evidence is lacking in many areas; research has explored specific outcomes but has not always compared the medicine against a wide range of alternative treatments. The existing studies provide limited insight into the full range of outcomes for all specific patient groups.

Key Studies & References NICE Guideline NG207: Peripheral arterial disease: diagnosis and management (Includes Naftidrofuryl assessment)

Common questions about Дузофарм (FAQ)

Q: How long after starting Duzopharm can you feel the effect?

Research evidence from clinical trials suggests that measurable clinical effects, such as an improvement in walking distance for the primary indication, are generally noted after two to three months of consistent use. It is noted that the intended effect is often associated with this intermediate-term timeframe rather than immediate relief.

Q: Can I take Duzopharm if I have liver problems?

Official regulatory documents advise caution when considering use in patients who have existing severe hepatic (liver) insufficiency. Because the medicine is processed by the body, regulatory documents note that monitoring or adjustment of the regimen may be a consideration.

Q: How strongly does Duzopharm affect blood pressure?

The medicine is scientifically classified as a vasodilator, meaning it causes blood vessels to widen. Regulatory information indicates that it may therefore have a mild effect on lowering blood pressure. This effect is one reason official guidance describes that caution is needed when the medicine is used alongside other products that also reduce blood pressure.

Q: What is 'withdrawal syndrome' when stopping Duzopharm?

Regulatory guidance describes that the medicine is discontinued gradually, typically achieved by reducing the dose over a period of two to four weeks. The official product documents mandate this slow withdrawal process but do not formally define or name a specific 'withdrawal syndrome.'

Q: Duzopharm: how long can it be taken safely?

Clinical studies that established the evidence for Duzopharm's primary indication generally involve observation periods lasting between three and six months. Official documents indicate that long-term effects beyond this studied timeframe are not fully established.

Q: What is the difference between Duzopharm and its generic?

The brand name Duzopharm contains the active ingredient Naftidrofuryl oxalate. By regulatory definition, any generic version contains the identical active ingredient and is required to meet the same standards for efficacy and safety as the brand-name product.

Q: Why should Duzopharm be taken with food (or without it)?

While official administration instructions permit the medicine to be taken either with or without food, patient information often suggests taking it during or immediately after a meal. This recommendation is intended to help reduce the occurrence of common, mild gastrointestinal side effects.

Q: Why is it important not to exceed the recommended duration of Duzopharm use?

Regulatory guidance highlights the importance of adhering to the prescribed duration because the medicine is made with an oxalate salt. This compound has been linked to the formation of calcium oxalate kidney stones and, in very rare instances, potential liver damage, which are classified as serious adverse reactions.

Q: Is it true that Duzopharm causes drowsiness?

Official regulatory documents and safety profiles classify adverse effects based on frequency of reporting. Drowsiness is not listed or categorized as a formally documented or commonly reported adverse reaction to this medicine.

Q: How does Duzopharm affect driving?

Official regulatory information for the medicine provides a statement regarding its impact on daily activities. It specifies that Duzopharm has no stated effect on a patient’s ability to drive a vehicle or to operate machinery.

Q: Are there special instructions for older people taking Duzopharm?

Official documents indicate that a specific dose adjustment is generally not required for older adults, provided they have normal renal (kidney) function. However, due to general physiological considerations, official documents indicate that careful monitoring may be a consideration.

Q: What should I do if the side effects of Duzopharm seem very strong?

Regulatory documents advise that if a patient suspects a rare but serious adverse reaction, such as liver damage, regulatory guidance states that seeking immediate medical guidance is necessary. The official product information cannot provide general, personalized advice on how to manage all side effects.

Q: How often should I have check-ups when taking Duzopharm long-term?

Regulatory documents do not formally define a standard check-up schedule for the general population. They do indicate that close surveillance and monitoring may be necessary for patients with certain specific conditions, such as existing severe kidney or liver impairment.

How to Store and Dispose of Дузофарм (Naftidrofuryl Oxalate)

Official regulatory documents define specific conditions required to store Дузофарм and maintain its stability throughout the labeled 30-month shelf life.

Required Storage Conditions

Requirement	Official Instruction
Temperature Limit	Do not store above 25 C (seventy-seven degrees Fahrenheit).
Protection	Store in the original package to protect from both light and moisture.
Child Safety	Must be kept out of the sight and reach of children.

Disposal

Formal labeling states there are “No special requirements for disposal” of the finished medicinal product. Unused or expired medicine and its packaging must be discarded in accordance with prevailing national and local regulations for pharmaceutical waste.